News

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin…

2 years ago

Petalfast Expands Cannabis Brand Sales & Trade Marketing Platform to Arizona, Announces Distribution Partnership with Consensus Holdings

The Company brings winning California route-through-market sales model to Arizona marketIRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Petalfast, a…

2 years ago

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

2 years ago

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical…

2 years ago

Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference

WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…

2 years ago

Sernova Announces Full Exercise of Share Purchase Warrants Expiring September 22, 2022

Additional $3.5M of capital raised from exercise of expiring warrantsLONDON, Ontario, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA)…

2 years ago

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri,…

2 years ago

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for…

2 years ago

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine…

2 years ago